High cholesterol is one of its primary drivers, and the limitations of existing treatments have long been one of medicine’s most urgent unsolved problems.
These are short, single-stranded DNA molecules engineered to bind with precision to specific genetic sequences and effectively silence them.
The target is a protein called PCSK9, which has become one of the most important focal points in cholesterol research over the past decade.
PCSK9 works by attaching to LDL receptors on liver cells, the very receptors responsible for pulling bad cholesterol out of the bloodstream.
When PCSK9 levels are high, fewer receptors are available, and LDL cholesterol accumulates in the blood, clogging arteries and raising the risk of heart disease.
By silencing the gene that produces PCSK9, the new treatment effectively removes the block, allowing the liver to clear far more cholesterol from circulation.
The goal is the same as it has always been: lower bad cholesterol, protect the heart, and keep people alive longer. »